Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 29, 2010 Brian Orelli	All Grown Up, With Cash to Burn Bristol-Myers is all drugs, all the time.
The Motley Fool August 12, 2011 David Williamson	What Happened to U.S. Pharma? How did the domestic pharmaceutical industry fare in the most recent quarter?
The Motley Fool May 21, 2009 Robert Steyer	The AstraZeneca Dilemma Can AstraZeneca produce enough new drugs to offset a series of upcoming patent expirations?
The Motley Fool January 28, 2009 Brian Orelli	A Mini-Pfizer in the Making Bristol-Myers Squibb looks like its setting itself up to be the next Pfizer.
The Motley Fool April 29, 2009 Brian Orelli	Parachutes, Cliffs, and Softer Landings Bristol-Myers Squibb faces a major patent cliff in a few years, and it's doing everything it can to make the fall as painless as possible. Early indications from yesterday's first-quarter earnings report look promising.
The Motley Fool January 28, 2005 Rich Duprey	Dentsply Dons a Smile Dental supply company rebounds in fourth quarter with record earnings and profits.
The Motley Fool November 17, 2009 Brian Orelli	Up 80%, It's Time to Sell Bristol-Myers to Mead Johnson: It's time to walk on your own. Investors will have an option of exchanging some or all of their Bristol-Myers shares for shares in Mead Johnson for a slight discount
The Motley Fool October 23, 2009 Brian Orelli	I Don't Need No Massive Merger Plavix's patent expiration is approaching, but Bristol-Myers Squibb is prepared.
The Motley Fool September 30, 2011 David Williamson	This Week in Health Care Pharma news about Pfizer, AstraZeneca, and the multibillion-dollar battle to replace the maligned blood-thinner warfarin.
Chemistry World April 29, 2014 Phillip Broadwith	Pfizer courts AstraZeneca megamerger US-based pharma behemoth Pfizer has publically announced its intention to make a merger offer to the UK's AstraZeneca, in a deal valued at around $100 billion.
The Motley Fool February 2, 2006 Stephen D. Simpson	AstraZeneca: Of Patents and Pipelines Losing Toprol-XL would be a blow, but not a fatal one. So what to do with AstraZeneca's stock? It might not be as cheap as Pfizer or Abbott Labs, but if the pipeline works out, it still seems like there's money to be made here.
The Motley Fool January 30, 2007 Rich Smith	Foolish Forecast: Dentsply's Whiter Smile The dental products supplier will report its fourth-quarter 2006 financial results shortly. Investors, here is what you can expect to see.
The Motley Fool April 29, 2011 Brian Orelli	Show Us the Money, Drugmakers Drugmakers have cash and they aren't afraid to use it -- on themselves.
The Motley Fool July 30, 2007 Brian Lawler	AstraZeneca's Yawner of a Quarter The pharma's second-quarter results are ho-hum. Investors may do well to take a look at some of the other big pharma stocks, which offer more compelling reasons to buy.
The Motley Fool April 24, 2007 Brian Lawler	MedImmune Not Immune to Takeovers MedImmune shops itself to AstraZeneca. MedImmune investors appear to be getting a pretty sweet deal.
The Motley Fool February 26, 2010 Brian Orelli	Drug Company Cost Cuts: Careful What You Wish For Research and development is the lifeblood of future revenue.
The Motley Fool April 27, 2006 Stephen D. Simpson	Investors Get Starry-Eyed for AstraZeneca Investors, while this British drug giant is getting its due from the market now in response to strong earnings, positive guidance, and more confidence in the future portfolio of drugs, remember to do your own due diligence first.
The Motley Fool October 28, 2004 Rich Duprey	Has Dentsply's Smile Dimmed? Dental supply company reports record earnings, but slipping sales in key markets. The stock was knocked down by about 4%.
The Motley Fool February 5, 2007 Billy Fisher	A Fresh Outlook at AstraZeneca Strong performance makes management happy at the European drug giant. As long as the company is able to continue the strong revenue growth from its major contributors, shareholders will be able to enjoy a prosperous 2007.
The Motley Fool February 12, 2007 Rich Duprey	Dentsply's New Supply of Growth The dental supply company takes a short-term sales hit as it reworks its distribution program. Investors, take note.
The Motley Fool January 28, 2011 Brian Orelli	Looking Ahead at Bristol-Myers Product approvals now will help with the upcoming patent cliff.
The Motley Fool October 14, 2010 Sean Williams	Should You Let AstraZeneca Go? Multiple drug patent expirations await. It's time to run away.
The Motley Fool July 29, 2004 Rich Duprey	Dentsply Makes Investors Smile The dental-supply company continues reporting solid profit and earnings growth. Dentsply looks as though it will continue to be a steady, consistent performer.
The Motley Fool January 12, 2010 Brian Orelli	J.P. Morgan Challenge: Making Money Off Molars Edition An overview of dental supply company, Dentsply.
The Motley Fool April 30, 2010 Brian Orelli	Living the Blockbuster Model AstraZeneca's top drugs provide top-line growth in the first quarter.
Chemistry World December 20, 2013 Patrick Walter	AstraZeneca shells out $4.1bn for diabetes business AstraZeneca has agreed to pay Bristol-Myers Squibb up to $4.1 billion for its share of the pharma giants' diabetes joint venture.
The Motley Fool February 1, 2008 Brian Lawler	AstraZeneca's Trying to Get Healthier Big pharma AstraZeneca tries to get back on track by reducing costs.
The Motley Fool May 1, 2007 Rich Duprey	Dentsply Opens Wide Strong European markets and double-digit specialty product sales boost the dental supply company. Investors, take note.
The Motley Fool July 30, 2010 Cliff D'Arcy	Which Is the Better Big Pharma? AstraZeneca is having a good 2010 -- and its shares are enjoying a great run, too. Here's how it compares to GlaxoSmithKline.
The Motley Fool March 2, 2004 Seth Jayson	The Shine at Schein The medical supplier continues its solid growth.
Chemistry World April 24, 2007 Victoria Gill	AstraZeneca Scoops up $15.6 Billion Vaccine Business AstraZeneca has joined the race to scoop up acquisition opportunities in the biologics sector with a $15.6 billion deal to buy U.S. vaccines and biotechnology company MedImmune.
The Motley Fool April 23, 2007 Rich Duprey	Foolish Forecast: Getting to the Root of Dentsply The dental supply company is set to report first-quarter 2007 financial results shortly. Investors, here is what you can expect to see.
The Motley Fool February 9, 2006 Stephen D. Simpson	Dentsply: Often Overlooked, but Solid Can the dental-care company reclaim its past growth rates? Investors, take note.
BusinessWeek December 29, 2010 Kelley & Cortez	AstraZeneca's Risky Bet on Drug Discovery Instead of acquisitions and diversification, AstraZeneca is determined to find new pills in its own labs.
The Motley Fool April 26, 2007 Brian Lawler	AstraZeneca's Announcement Overshadows Earnings AstraZeneca releases first-quarter financial results. Investors, take note.
The Motley Fool November 2, 2011 Prabhat Sakya	AstraZeneca vs. GlaxoSmithKline If you could only invest in one of these companies, which would it be?
The Motley Fool September 23, 2004 Rich Duprey	Dentsply Is More Than a Mouthful Dental supply company increases cash dividend by 14% amid torrid growth.
The Motley Fool July 30, 2009 Brian Orelli	A Little Help From the Enemy Unfortunately, it won't last. AstraZeneca went over a small patent cliff, but its competitors were nice enough to throw it some climbing gear.
The Motley Fool July 27, 2006 Stephen D. Simpson	AstraZeneca Needs a Rest The stock isn't too expensive, but it's no longer a bargain.
Chemistry World January 28, 2010 Nina Notman	AstraZeneca's workforce slashed again Pharma giant AstraZeneca is to cut another 8,000 jobs globally over the next four years - with approximately 1,800 additional research and development staff to be lost.
The Motley Fool November 30, 2009 Brian Orelli	Making Money More Efficiently Drug companies shape up, and it shows in their margins.
The Motley Fool September 10, 2008 Brian Orelli	Are Drug Companies Being Shortsighted With R&D? Cutting research and development spending could be like playing with fire for pharmaceutical companies.
Chemistry World October 25, 2013 Emily James	AstraZeneca to close environmental lab and cut 71 jobs The 71 employees at the Brixham Environmental Laboratory in Devon, UK. will lose their jobs in March 2014, as the laboratory's environmental operations are not a core part of the company's strategy to develop innovative new medicines.
The Motley Fool May 12, 2006 Stephen D. Simpson	Drilling Into Dentsply Sometimes, investors can get a fair sense of a company in just a few minutes of reading SEC filings. Other times, you've got to dig a little deeper to see the real value. That may be the case with leading dental company Dentsply International.
The Motley Fool February 10, 2006 Stephen D. Simpson	Sybron's Gap-Toothed Grin Well-run and widely regarded dental franchise Sybron just looks too expensive. Investors, take note.
The Motley Fool July 26, 2007 Ryan Fuhrmann	Zimmer Simmers The maker of hip and knee replacements gets a leg up on the market. Investors, take note.
The Motley Fool February 17, 2011 Alex Dumortier	Seize Your Chance to Beat the Pros! An area of genuine opportunity for the small investor. Spinoffs remain an underappreciated area in which the individual investor actually gains an edge over institutions.
The Motley Fool October 21, 2008 Brian Orelli	The World Is Saving Pfizer The pharma company experienced a double-digit decrease in U.S. sales in the third quarter. Ouch.
The Motley Fool November 23, 2005 Stephen D. Simpson	Is It Safe for Patterson? A tougher market and high valuation don't make this dental, veterinary, and rehab supplier an especially compelling investment idea.
The Motley Fool December 13, 2005 Stephen D. Simpson	A Toothache at Sybron Dental Investors bail out in the wake of the company's fourth-quarter announcement.